留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

急性高山病防治研究进展

熊娟 鹿辉 王荣 贾正平

熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
引用本文: 熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001

急性高山病防治研究进展

doi: 10.3969/j.issn.1006-0111.2017.02.001
基金项目: 国家自然科学基金(81401552)

Research progress on prevention and treatment of acute mountain sickness

  • 摘要: 高海拔未习服人群快速进入高海拔地区易患急性高山病(acute mountain sickness,AMS)。AMS是一种以头痛为主要症状并伴有肠胃不适、眩晕、疲劳和失眠等症状的自限性疾病。虽然对AMS已经开展了大量研究,但业内对其病理机制以及有效防治等方面的认识还非常有限。深入认识AMS的诊断方法、危险因素和病理生理机制,对提出针对AMS有效的防治措施十分重要。本文基于课题组的前期研究和相关文献,较为系统地综述AMS的临床诊断、危险因素、病理生理机制和防治措施。
  • [1] Bartsch P,Swenson ER. Clinical practice:Acute high-altitude illnesses[J]. N Engl J Med,2013,368(24):2294-2302.
    [2] Gonggalanzi,Labasangzhu,Nafstad P,et al. Acute mountain sickness among tourists visiting the high-altitude city of Lhasa at 3658 m above sea level:a cross-sectional study[J]. Arch Public Health,2016,74(1):1-7.
    [3] Fruhauf A,Burtscher M,Pocecco E,et al. Subjective assessment of acute mountain sickness:investigating the relationship between the Lake Louise Self-Report,a visual analogue scale and psychological well-being scales[J]. Springerplus,2016,5(1):1646.
    [4] Wu J,Chen Y,Luo Y. Evaluation of the visual analog score (VAS) to assess acute mountain sickness (AMS) in a hypobaric chamber[J]. PLoS One,2014,9(11):e113376.
    [5] Fiore DC,Hall S,Shoja P. Altitude illness:risk factors,prevention,presentation,and treatment[J]. Am Fam Physician,2010,82(9):1103-1110.
    [6] Richalet JP,Larmignat P,Poitrine E,et al. Physiological risk factors for severe high-altitude illness:a prospective cohort study[J]. Am J Respir Crit Care Med,2012,185(2):192-198.
    [7] DiPasquale DM,Muza SR,Gunn AM,et al. Evidence for cerebral edema,cerebral perfusion,and intracranial pressure elevations in acute mountain sickness[J]. Brain Behav,2016,6(3):e00437.
    [8] Fischer R,Vollmar C,Thiere M,et al. No evidence of cerebral oedema in severe acute mountain sickness[J]. Cephalalgia,2004,24(1):66-71.
    [9] Bailey DM,Roukens R,Knauth M,et al. Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache[J]. J Cereb Blood Flow Metab,2006,26(1):99-111.
    [10] Dubowitz DJ,Dyer EA,Theilmann RJ,et al. Early brain swelling in acute hypoxia[J]. J Appl Physiol,2009,107(1):244-252.
    [11] Mairer K,Gobel M,Defrancesco M,et al. MRI evidence:acute mountain sickness is not associated with cerebral edema formation during simulated high altitude[J]. PLoS One,2012,7(11):e50334.
    [12] Wilson MH,Milledge J. Direct measurement of intracranial pressure at high altitude and correlation of ventricular size with acute mountain sickness:Brian Cummins' results from the 1985 Kishtwar expedition[J]. Neurosurgery,2008,63(5):970-974; discussion 974-975.
    [13] Hackett PH,Roach RC. High-altitude illness[J]. N Engl J Med,2001,345(2):107-114.
    [14] Van Osta A,Moraine JJ,Melot C,et al. Effects of high altitude exposure on cerebral hemodynamics in normal subjects[J]. Stroke,2005,36(3):557-560.
    [15] Julian CG,Subudhi AW,Hill RC,et al. Exploratory proteomic analysis of hypobaric hypoxia and acute mountain sickness in humans[J]. J Appl Physiol,2014,116(7):937-944.
    [16] Lopez JI,Holdridge A,Mendizabal JE. Altitude headache[J]. Curr Pain Headache Rep,2013,17(12):383.
    [17] Wilson MH,Davagnanam I,Holland G,et al. Cerebral venous system and anatomical predisposition to high-altitude headache[J]. Ann Neurol,2013,73(3):381-389.
    [18] Wilson MH,Imray CH,Hargens AR. The headache of high altitude and microgravity——similarities with clinical syndromes of cerebral venous hypertension[J]. High Alt Med Biol,2011,12(4):379-386.
    [19] Lu H,Wang R,Xiong J,et al. In search for better pharmacological prophylaxis for acute mountain sickness:looking in other directions[J]. Acta Physiol (Oxf),2015,214(1):51-62.
    [20] Schumacker PT. Lung cell hypoxia:role of mitochondrial reactive oxygen species signaling in triggering responses[J]. Proc Am Thorac Soc,2011,8(6):477-484.
    [21] Kayser B,Dumont L,Lysakowski C,et al. Reappraisal of acetazolamide for the prevention of acute mountain sickness:a systematic review and meta-analysis[J]. High Alt Med Biol,2012,13(2):82-92.
    [22] Luks AM,McIntosh SE,Grissom CK,et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness:2014 update[J]. Wilderness Environ Med,2014,25(4 Suppl):S4-14.
    [23] Tang E,Chen Y,Luo Y. Dexamethasone for the prevention of acute mountain sickness:systematic review and meta-analysis[J]. Int J Cardiol,2014,173(2):133-138.
    [24] Pandit A,Karmacharya P,Pathak R,et al. Efficacy of NSAIDs for the prevention of acute mountain sickness:a systematic review and meta-analysis[J]. J Community Hosp Intern Med Perspect,2014,4(4).
    [25] Lipman GS,Kanaan NC. Ibuprofen for prevention of acute mountain sickness:is bigger really better[J]. Wilderness Environ Med,2013,24(2):177-178.
    [26] Sun L,Ding MJ,Cai TC,et al. Development and preliminary test of a new plateau hyperbaric chamber[J]. Am J Emerg Med,2015,33(10):1497-1500.
    [27] Shah NM,Hussain S,Cooke M,et al. Wilderness medicine at high altitude:recent developments in the field[J]. OAJSM,2015,6:319-328.
    [28] Grissom CK,Roach RC,Sarnquist FH,et al. Acetazolamide in the treatment of acute mountain sickness:Clinical efficacy and effect on gas exchange[J]. Ann Intern Med,1992,116(6):461-465.
    [29] Swenson ER. Pharmacology of acute mountain sickness:Old drugs and newer thinking[J]. J Appl Physiol,2016,120(2):204-215.
  • [1] 张景翔, 朱琳, 邢信昊, 王欣荣, 王彦.  晕动病防治研究进展 . 药学实践与服务, 2022, 40(3): 199-201, 247. doi: 10.12206/j.issn.1006-0111.202101018
    [2] 谢华, 王延玲, 王昌, 李文斌, 贾正平, 王荣.  美托洛尔对急进海拔3400 m大鼠的心肌保护作用研究 . 药学实践与服务, 2018, 36(3): 238-242. doi: 10.3969/j.issn.1006-0111.2018.03.010
    [3] 熊娟, 鹿辉, 王荣, 贾正平.  超重可能是急性高山病的危险因素:一项Meta分析 . 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
    [4] 高越, 陈安妮, 赵亚红, 薛丹, 安泳潼, 柴逸峰, 张海.  养心氏片防治慢性缺血性心力衰竭及急性心肌缺血再灌注损伤的实验研究 . 药学实践与服务, 2016, 34(5): 403-407,415. doi: 10.3969/j.issn.1006-0111.2016.05.006
    [5] 马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平.  预防和治疗高原病药物临床用药参考 . 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
    [6] 李金英, 许恒忠.  加强医院药品管理的措施 . 药学实践与服务, 2004, (4): 246-247.
    [7] 蒯丽萍, 顾文华, 陈静.  FDA防治吸入性炭疽病的抗微生物药物研发指南 . 药学实践与服务, 2004, (5): 305-307.
    [8] 杨曦, 赵冲, 张重军, 殷嘉明, 卢珊, 李凤阁.  做好军区部队防治“非典”药材保障工作的措施与经验 . 药学实践与服务, 2004, (1): 33-35.
    [9] 张荣, 张华.  医院普通制剂包装中存在的问题及改进措施 . 药学实践与服务, 2003, (2): 111-113.
    [10] 孙晓红, 陈盛新, 舒丽芯.  军队药材供应模式的现状及改革措施 . 药学实践与服务, 2003, (3): 180-181,183.
    [11] 李菱.  中小药房提高发药质量的几点措施 . 药学实践与服务, 2003, (2): 119-120.
    [12] 李驰荣.  加强我院西药房工作质量的几点措施 . 药学实践与服务, 2001, (6): 370-371.
    [13] 石长发, 丁大勇, 孟庆彪, 陈玉铭.  在大输液生产中保证微孔滤膜完好性的措施 . 药学实践与服务, 2001, (2): 127-127.
    [14] 马传新, 刘邦国, 马晓燕.  投药错误原因分析及防范措施 . 药学实践与服务, 2000, (3): 175-177.
    [15] 祝秋芬, 赵爱国.  我院处方规范化管理措施 . 药学实践与服务, 1995, (5): 317-319.
    [16] 何廉卿.  临床药物不良反应及其防治 . 药学实践与服务, 1991, (4): 48-50.
    [17] 吴健, 杨爱梅.  防治褥疮液治疗褥疮51例 . 药学实践与服务, 1989, (1): 36-37.
    [18] 陶纪值.  防治运动病新药—膜控释型东莨菪碱贴片 . 药学实践与服务, 1989, (3): 26-27.
    [19] 吴永远, 苏开仲.  铁剂急性中毒的临床症状及其防治 . 药学实践与服务, 1989, (3): 48-50.
    [20] 陆晓和.  西米替丁的不良反应及其防治 . 药学实践与服务, 1986, (4): 34-36.
  • 加载中
计量
  • 文章访问数:  3152
  • HTML全文浏览量:  296
  • PDF下载量:  366
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-08-30
  • 修回日期:  2016-11-07

急性高山病防治研究进展

doi: 10.3969/j.issn.1006-0111.2017.02.001
    基金项目:  国家自然科学基金(81401552)

摘要: 高海拔未习服人群快速进入高海拔地区易患急性高山病(acute mountain sickness,AMS)。AMS是一种以头痛为主要症状并伴有肠胃不适、眩晕、疲劳和失眠等症状的自限性疾病。虽然对AMS已经开展了大量研究,但业内对其病理机制以及有效防治等方面的认识还非常有限。深入认识AMS的诊断方法、危险因素和病理生理机制,对提出针对AMS有效的防治措施十分重要。本文基于课题组的前期研究和相关文献,较为系统地综述AMS的临床诊断、危险因素、病理生理机制和防治措施。

English Abstract

熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
引用本文: 熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
参考文献 (29)

目录

    /

    返回文章
    返回